OTS have already identified a number of cancer-specific-genes that would be applicable for development of molecular-targeted anti-cancer therapies. OTS has been pursuing the medicinal discovery research with understanding the subcellular localization, mode of function, and immunogenicity of the target cancer-specific-genes.
- Investor Relations28/06/2018Announcement of the press release from QST regarding the publication of novel α-emitter radioisotope-labeled therapy for synovial sarcoma
- Investor Relations05/03/2018Announcement of the progress of Phase III clinical study of the cancer-specific peptide vaccine S-588410
- Investor Relations01/03/2018Announcement of research collaboration between OTS’s subsidiary company and Japanese Foundation for Cancer Research (JFCR)
Our service offers comprehensive analysis of TCR repertoire from blood and tissue samples using next generation sequencing technology. A detailed data analysis will be performed. We ensure that we will perform this service consistently, from sample preparation to delivering results.
and Safer Cancer Treatments
Pursuing “To develop anti-cancer medicine and anti-cancer therapy with high efficacy and minimum risk of adverse events, and to win the war against cancer”, OTS has been conducting research and development, by collaborating with Professor Yusuke Nakamura, a genomics pioneer.